LIVE WEBINAR: Myeloid Malignancy MRD


Tuesday June 29, 2021 2:00 - 3:00PM Eastern


This interactive live webinar is part 6 of the Emerging and Evolving Biomarkers Series

Description:

This webinar will provide an introductory overview of measuring residual disease in myeloid neoplasms, with a focus on acute myeloid leukemia.  This talk will summarize the clinical need, laboratory approaches, and future opportunities and challenges for this testing.

Learning Objectives:

  • Review clinical need and opportunities for detecting measurable residual disease (MRD) in myeloid neoplasms, with focus on acute myeloid leukemia
  • Discuss challenges with detecting MRD
  • Describe technical approaches for detecting MRD in the clinical laboratory
  • Review recent literature and progress in this field



    Speaker:
    David Wu, MD, PhD
    Moderator:
    Lauren Ritterhouse, MD, PhD

    Duration: 1 Hour
    Level of Instruction: Basic

    This activity is supported by educational funding provided by Amgen and by an educational grant from Lilly (for further information concerning Lilly grant funding visit www.lillygrantoffice.com). Grant supporters had no control over its content. No personally-identifiable information regarding you is provided to any grant supporters.

    How to Register:
    1. Click the "Register Now" Button
    2. Log in using your AMP credentials. If you do not have an AMP account, Create a FREE account by clicking here.
    3. Complete the "Demographic questionnaire for Emerging and Evolving Biomarkers Series" before the webinar date. You will only need to do this once for the entire series.

    Continuing Education Credit Information

    CME credit: 1.0
    CMLE credit: 1.0 
    Last day to claim credit: July 29, 2021

    Accreditation Statements
    AMA PRA Category 1 Credit(s)
    This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Society for Clinical Pathology (ASCP) and Association for Molecular Pathology (AMP). The American Society for Clinical Pathology (ASCP) is accredited by the ACCME to provide continuing medical education for physicians.

    The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

    CMLE
    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours of CMLE credit. ASCP CMLE credit hours are acceptable for the ASCP Board of Certification (BOC) Certification Maintenance Program (CMP). CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity.

    AMP is pleased to collaborate in the Immunotherapy Collaborative of Oncology Networked Communities, IC-ONC.  IC-ONC is a global information network in which multidisciplinary healthcare providers, responsible for treating patients with cancer, are connected via education.  

    Please be sure to visit www.ic-onc.org to learn more about the collaborative and all it has to offer.


    Note: Join the AMP Family for discounted access to the most current educational resources!

    All sales are final. No refunds will be issued.

    No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentation